Preoperative serum circulating microRNAs as potential biomarkers for chronic postoperative pain after total knee replacement by Giordano, Rocco et al.
 
  
 
Aalborg Universitet
Preoperative serum circulating microRNAs as potential biomarkers for chronic
postoperative pain after total knee replacement
Giordano, Rocco; Petersen, Kristian Kjær; Andersen, Hjalte Holm; Lichota, Jacek; Valeriani,
Massimiliano; Simonsen, Ole; Arendt-Nielsen, Lars
Published in:
Molecular Pain
DOI (link to publication from Publisher):
10.1177/1744806920962925
Creative Commons License
CC BY-NC 4.0
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Giordano, R., Petersen, K. K., Andersen, H. H., Lichota, J., Valeriani, M., Simonsen, O., & Arendt-Nielsen, L.
(2020). Preoperative serum circulating microRNAs as potential biomarkers for chronic postoperative pain after
total knee replacement. Molecular Pain, 16. https://doi.org/10.1177/1744806920962925
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Research Article
Preoperative serum circulating
microRNAs as potential biomarkers
for chronic postoperative pain after
total knee replacement
Rocco Giordano1 , Kristian Kjær Petersen1,2,
Hjalte Holm Andersen2, Jacek Lichota3, Massimiliano Valeriani2,4,
Ole Simonsen5 and Lars Arendt-Nielsen2
Abstract
Background: Chronic postoperative pain affects approximately 20% of patients with knee osteoarthritis after total knee
replacement. Circulating microRNAs can be found in serum and might act as biomarkers in a variety of diseases. The current
study aimed to investigate the preoperative expression of circulating microRNAs as potential predictive biomarkers for the
development of chronic postoperative pain in the year following total knee replacement.
Methods: Serum samples, collected preoperatively from 136 knee osteoarthritis patients, were analyzed for 21 circulatory
microRNAs. Pain intensity was assessed using a visual analog scale before and one year after total knee replacement. Patients
were divided into a low-pain relief group (pain relief percentage <30%) and a high-pain relief group (pain relief percentage
>30%) based on their pain relief one year after total knee replacement, and differences in microRNAs expression were
analyzed between the two groups.
Results:We found that three microRNAs were preoperatively dysregulated in serum in the low-pain relief group compared
with the high-pain relief group. MicroRNAs hsa-miR-146a-5p, -145-5p, and -130 b-3p exhibited fold changes of 1.50, 1.55, and
1.61, respectively, between the groups (all P values< 0.05). Hsa-miR-146a-5p and preoperative pain intensity correlated
positively with postoperative pain relief (respectively, R¼ 0.300, P¼ 0.006; R¼ 0.500, P< 0.001).
Discussion: This study showed that patients with a low postoperative pain relief present a dysregulation of circulating
microRNAs. Altered circulatory microRNAs expression correlated with postoperative pain relief, indicating that
microRNAs can serve as predictive biomarkers of pain outcome after surgery and hence may foster new strategies for
preventing chronic postoperative pain after total knee replacement (TKR).
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Introduction
Osteoarthritis (OA) is the most frequent painful muscu-
loskeletal diagnosis in the elderly population and the
most prominent cause of disability.1 Total knee
1Center for Neuroplasticity and Pain, SMI, Department of Health Science
and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark
2Center for Sensory-Motor Interaction, Department of Health Science and
Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark
3Laboratory of Metabolism Modifying Medicine, Department of Health
Science and Technology, Faculty of Medicine, Aalborg University, Aalborg,
Denmark
4Child Neurology Unit, Department of Neuroscience and
Neurorehabilitation, Headache Center, Bambino Gesu Children’s Hospital,
Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
5Orthopedic Surgery Research Unit, Aalborg University Hospital, Aalborg,
Denmark
Corresponding Author:
Lars Arendt-Nielsen, Center for Sensory-Motor Interaction, Department
of Health Science and Technology, Faculty of Medicine, Aalborg University,
Fredrik Bajers Vej 7, D3, DK-9220 Aalborg, Denmark.
Email: lan@hst.aau.dk
Molecular Pain
Volume 0: 1–10
! The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1744806920962925
journals.sagepub.com/home/mpx
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution
of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-
us/nam/open-access-at-sage).
replacement (TKR) is the end-stage treatment of knee
OA and provides pain relief for the majority of patients
with severe OA. However, around 20% of knee OA
patients will experience chronic postoperative pain
after TKR surgery.2,3 Several studies have found that
high preoperative pain intensities4,5 and sensitization of
central pain pathways6 act as predictors for chronic
postoperative pain following TKR.
Recently, an exploratory study found that certain pre-
operative pro-inflammatory cytokines were associated
with the development of chronic postoperative pain fol-
lowing TKR.7 There is evidence that pro-inflammatory
and anti-inflammatory cytokines are involved in pain.8
Consequently, there is increasing interest in the evalua-
tion of small non-coding RNAs, defined by Sommer
et al. as “master switches,” acting in the development
and maintenance of inflammation and pain.9 The
action of circulating non-coding RNAs, already verified
in pathologies such as cancer and autoimmune disease, is
receiving increasing attention in the pain field.10–12 In
this context, studies have shown that small non-coding
RNAs are directly involved in the production of
cytokines.13,14
This indicates that the preoperative assessment of
non-coding RNAs could be a potential prognostic bio-
marker venue in terms of assessing the risk for chronic
postoperative pain following TKR and may represent a
way to explore new therapeutic opportunities.
MicroRNA (miRNA) is a group of small non-coding
RNAs (20–25 nucleotides)15 involved in post-
transcriptional gene expression regulation, with more
than 7000 miRNAs recognized in human between pre-
cursor and mature structure.16 Unlike the majority of
miRNAs, which are usually detectable intracellularly,
circulating or extracellular miRNAs have also been
found in the interstitial environment, cell culture
media, and in different biological fluids such as serum
or plasma.17–20 Moreover, circulating miRNAs are
known to be protected from the action of degradation
enzymes, due to their inclusion in extracellular micro-
vesicles18 or formation of protein-miRNA complexes.19
This makes the circulating miRNAs highly stable and
their expression can be quantified in body fluids,
making them suitable to act as potential biomarkers.21
Circulating miRNAs have been found to be dysregulated
in patients with various chronic pain conditions includ-
ing complex regional pain syndrome,22 migraine,23
peripheral neuropathy,24 and fibromyalgia when com-
pared to healthy controls.24 Recently, a study highlight-
ed the different functions as well as potential diagnostic
and predictive value of miRNAs in various pain states,25
but no study thus far has assessed the potential use of
circulating miRNA as predictive biomarkers for chronic
postoperative pain. The current study aimed to investi-
gate the preoperative expression of circulating miRNAs
validated or predicted in previous study to be associated
with OA pain and inflammation, as potential predictive
biomarkers for the development of chronic postopera-
tive pain one year after TKR.
Material and methods
Patients
One hundred thirty-six patients with a knee osteoarthri-
tis (KOA) scheduled for TKR were recruited consecu-
tively from the outpatient clinic at Hospital Vendsyssel,
Frederikshavn, Denmark, and tested for preoperative
miRNAs expression in serum. Patients with other diag-
nosed pain conditions (e.g., hip OA, rheumatoid arthri-
tis, fibromyalgia, and neuropathic pain), sensory
dysfunction, or mental impairment were excluded from
the study. Radiological KOA progression was evaluated
using the Kellgren and Lawrence (KL) score.26 The KL
score is a radiological assessment score of knee OA. The
score ranges from 0 (no OA) to 4 (severe OA).26
The patients were asked not to take any analgesic
medication, such as non-steroidal anti-inflammatory
drugs or paracetamol, 24 h before the pain scoring exam-
ination. The study was approved by The North
Denmark Region Committee on Health Research
Ethics (N-20120015) and conducted in accordance with
the Helsinki Declaration. All patients read and signed an
informed consent form prior to enrollment.
Pain assessment
Before surgery and one year after, the peak pain inten-
sity within the last 24 h was collected (using the visual
analog scale, hereafter VAS). The patients were asked to
rate their pain intensity on the VAS scale from “0–10”
where “0” represents “no pain” and “10” represents
“worst pain imaginable.” The patients were divided
into two groups based on the percentage of postopera-
tive pain relief (the difference between pre- and postop-
erative VAS scores divided by preoperative VAS score).
Patients achieving >30% pain relief after TKR were
assigned to the “high-pain relief” group, whereas
patients who achieved <30% pain relief were assigned
to the “low-pain relief” group. This classification for the
patients was based on the minimum clinical relevance
observed in previous study.27
Blood withdrawal and microRNA isolation
Venous blood was collected following standard proce-
dures from patients before they underwent the surgery,
between 07:30 and 09:00 in the morning. For the real-
time PCR (qRT-PCR), 9ml of whole blood was with-
drawn in an untreated tube. After collection, the whole
blood was left at room temperature for 15min and
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allowed to clot; the serum was then separated from clot-
ted cells by low-speed centrifugation (3000 rpm) for
15min to allow the serum separation. The serum
obtained was stored at 80C until used. After thawing
on ice, circulating miRNAs were isolated from 200 ml of
serum using miRNeasy Serum/Plasma Advanced Kit
(QIAGEN, Hilden, Germany) according to the manu-
facturer’s instructions. As a positive control, 3.5ml
(1.6 108 copies/ml) of Serum/Plasma Spike-in Control
cel-miR-39-3p (QIAGEN, Hilden, Germany) was added
to each reaction during the extraction protocol.
MicroRNA array expression
Isolated miRNAs were retrotranscribed to cDNA, using
miScript II RT Kit (QIAGEN, Hilden, Germany) in a
thermocycler (Applied Biosystems, Foster City, CA,
USA) at 37C for 1 h with heat inactivation of the
retro-transcriptase at 95C for 5min. To perform qRT-
PCR, miScript SYBRVR Green qPCR Kit (QIAGEN,
Germany) was added to each sample. Furthermore,
this mixture was aliquoted into the wells of Custom
miScript miRNA PCR Array (QIAGEN, Germany).
The cDNA for every patient was analyzed for 21 puta-
tive miRNAs candidates known to be associated with
inflammation, pain, and cartilage degeneration. Plates
were pre-manufactured by QIAGEN and contained spe-
cific primers for miRNAs of interest based on previous
evidence of their detection in human body fluids, and
their involvement in pathological OA pathways,
inflammation process, and findings of direct connections
with pain sensation (see Table 1). Thermal cycling con-
ditions consisted of a hot start at 95C for 15min fol-
lowed by 40 cycles of each qPCR step: (denaturation)
94C for 15 s, (annealing) 55C for 30 s and (extension)
70C for 30 s (AriaMx Agilent Technologies, Santa
Clara, CA, USA). A melting curve analysis was carried
out to ensure the specificity of the corresponding qRT-
PCR reactions. The Cycle quantification (Cq) data
obtained setting a single threshold of 12 between the
assays using Agilent Aria software 5.1 (Agilent
Technologies, Santa Clara, CA, USA), exported to a
Microsoft Excel file (Microsoft 2016) and subsequently
uploaded in Statistical Package for Social Sciences
(SPSS, v. 25, IBM).
Statistical analysis
Before the statistical analysis, the raw Cq values were
normalized using the Global Mean normalization
method on the expression of all miRNA assays.51
Initially, patient demographics were calculated for the
two groups with chi-square tests for categorical data
and t-tests for continuous data. The qRT-PCR data
were transformed into the fold change domain, defined
as measure describing how much a quantity changes
between an original and a subsequent measurement.
Unpaired Student’s t-tests were used to compare the nor-
malized Cq values for each miRNA between the two
groups of patients. The data have been visualized in a
Table 1. MicroRNA candidates list and list of microRNA sequences contained in the RT-qPCR customized array.
miRNA miRBase# miRNA sequence References
hsa-miR-146a-5p MIMAT0000449 ugagaacugaauuccauggguu 28,29
hsa-miR-29a-3p MIMAT0000086 uagcaccaucugaaaucgguua 30,31
hsa-miR-29b-3p MIMAT0000100 uagcaccauuugaaaucaguguu 31
hsa-miR-183-5p MIMAT0000261 uauggcacugguagaauucacu 32
hsa-miR-149-5p MIMAT0000450 ucuggcuccgugucuucacuccc 33
hsa-miR-145-5p MIMAT0000437 guccaguuuucccaggaaucccu 34
hsa-miR-16-5p MIMAT0000069 uagcagcacguaaauauuggcg 35
hsa-miR-103a-3p MIMAT0000101 agcagcauuguacagggcuauga 36
hsa-miR-320a MIMAT0000510 aaaagcuggguugagagggcga 36,37
hsa-miR-374b-5p MIMAT0004955 auauaauacaaccugcuaagug 36
hsa-miR-93-5p MIMAT0000093 caaagugcuguucgugcagguag 38
hsa-miR-19a-3p MIMAT0000073 ugugcaaaucuaugcaaaacuga 39
hsa-miR-19b-3p MIMAT0000074 ugugcaaauccaugcaaaacuga 39,40
hsa-miR-195-5p MIMAT0000461 uagcagcacagaaauauuggc 41,42
hsa-miR-92a-3p MIMAT0000092 uauugcacuugucccggccugu 39,40
hsa-miR-130a-3p MIMAT0000425 cagugcaauguuaaaagggcau 43
hsa-miR-130b-3p MIMAT0000691 cagugcaaugaugaaagggcau 44,45
hsa-miR-17-5p MIMAT0000070 caaagugcuuacagugcagguag 39
hsa-miR-155-5p MIMAT0000646 uuaaugcuaaucgugauagggguu 29,46,47
hsa-miR-106b-5p MIMAT0000680 uaaagugcugacagugcagau 48
hsa-miR-34a-5p MIMAT0000255 uggcagugucuuagcugguugu 49,50
miRNA: microRNA.
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volcano plot, combining P values (y-axis) with the fold
changes (x-axis), thus highlighting miRNAs with higher
or lower levels of expression. Correlations were con-
ducted using Pearson’s correlation coefficients. Linear
regression models were constructed to predict the pain
relief following TKR, using the preoperative pain inten-
sity and the miRNAs, which were significantly different
between the two groups. Furthermore, linear regressions
were utilized to identify independent preoperative pre-
dictive factors based on the miRNAs. Data analysis was
performed in SPSS software V.25 (IBM, Armonk, NY,
USA). P< 0.05 was considered significant.
In silico target prediction
A gene target analysis was conducted for the differen-
tially expressed miRNAs to identify genes that represent
putative targets. In silico prediction analyses were per-
formed using DIANA-Tool TarBase v.8,52 choosing the
predicted targeted mRNA genes by their prediction
score with a value between 0.5 and 1.0. To determine
the biological relevance of the predicted mRNA genes
targeted by the miRNAs, gene ontology (GO) analysis
was subsequently explored using PANTHER classifica-
tion system53 and Reactome (www.reactome.org).
Manual curation of targets associated with the immune
system process, biological regulation, cellular process,
and response to stimuli was performed.
Results
Demographics
Of 136 patients with KOA (82 female), 114 patients
(84%) had pain relief percentage >30% (high-pain
relief group) and 22 patients (16%) had pain relief per-
centage <30% (low-pain relief group). No significant
differences were found between the two groups regard-
ing preoperative patient demographics or KL (Table 2).
Moreover, no statistical difference was found for preop-
erative pain intensity in patients when subdivided for
gender (P¼ 0.944). From the 82 females enrolled in the
study, 82% were in the high-pain relief group and 18%
in the low-pain relief group. From the 54 men enrolled in
the study, 87% were in the high-pain relief group and
13% in the low-pain relief group.
MiRNA serum assays quality control
MiRNAs amplification cut-off was set at 35 cycles
(Figure S1). Moreover, to avoid “false positive” results,
a melt curve analysis was carried out to ensure the spe-
cificity of the corresponding RT-qPCR reactions. Figure
S2 shows that the assessed miRNAs peak at the same
time as the positive control cel-miR-39-3p (both peak at
temperatures of 76.5C). Conversely, the PPC (internal
PCR positive control) peaked at higher temperatures
(81.5C). The single aligned peak for assessed miRNA
and cel-miR-39-3p suggests that no unspecific amplicons
were produced.
Differential expression of miRNAs in patients with
low-pain relief following TKR
Three miRNAs were differentially expressed between
low-pain relief and high-pain relief group (a volcano
plot is displayed in Figure 1). Hsa-miR-146a-5p (fold
change¼ 1.50 0.86 SD, P value¼ 0.021), hsa-miR-
145-5p (fold change¼ 1.55 1.24 SD, P value¼ 0.037),
and hsa-miR-130b-3p (fold change¼ 1.61 1.4 SD,
P value¼ 0.039) had a significantly higher expression in
the low-pain relief group relative to the high-pain group.
Prediction of postoperative pain relief
Pooling all patient data showed significant Pearson cor-
relations between pain relief and preoperative pain
intensity (R¼ 0.500, P< 0.001) and hsa-miR-146a-5p
(R¼ 0.300, P¼ 0.006). Furthermore, linear regression
models were established to investigate the predictive
value using the significant miRNAs hsa-miR-146a-5p,
hsa-miR-130b-3p, hsa-miR-145-5p, and preoperative
pain intensity. Model 1 consisted of all the parameters
with a predictive value (R2) of 30% and identified pre-
operative pain intensity (P< 0.001) as significant factors
(Table 3). Model 2 was constructed using a backward
selection of the parameters included in model 1 and iden-
tified preoperative pain intensity (P< 0.001) as a signif-
icantly independent parameter for postoperative pain
Table 2. Demographic characteristics of sub grouped patients with severe knee osteoarthritis before total knee replacement.
High pain relief Low pain relief P value
Number of patients, n 114 22
Sex, female, % 58.7 68.1
Preoperative pain VAS score, cm, mean SEM 6.56 1.8 6.32 1.8 0.58
BMI, kg/m2, mean SEM 28.8 4.6 30.78 4.6 0.08
Age, y, mean SEM 69.03 8.7 68.00 10.1 0.62
KL, mean (range) 3.77 (2–4) 3.68 (2–4) 0.43
BMI: body mass index; KL: Kellgren and Lawrence radiological scores; SEM: standard error of the mean; VAS: visual analog scale (0–10).
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relief prediction with a value of R2 of 30% and showed a
trend of hsa-miR-146a-5p (P¼ 0.06) (Table 3, model 2).
Potential target mRNA genes of differentially
expressed circulating miRNAs
In silico target prediction analyses, through DIANA-
TarBase v.8, were performed to highlight the potential
mRNA targets of the dysregulated miRNAs. An mRNA
was considered a potential target if it has been validated
with high/low throughput experiment and if its prediction
score was between 0.5 and 1.0. Using these criteria, the
potential number of mRNA targets for the hsa-miR-
146a-5p was 103, for hsa-miR-145-5p was 35, and for
hsa-miR-130b-3p was 337. All the targeted genes were
analyzed for the GO analysis of the biological processes
(Figure 2). The majority of the identified gene targets
were involved in various cellular and metabolic process-
es. Our interest in qualitative exploration were genes
related to sensory transduction, inflammatory response,
and neuronal sensitization. The interleukin-1 receptor-
associated kinase 1 (IRAK1) gene was found to be tar-
geted by hsa-miR-146a-5p and is involved broadly in
cytokine-mediated signaling as well as the toll-like recep-
tor signaling pathways.54,55 Moreover, the hsa-miR-145-
5p, which was expressed at higher levels in the low-pain
relief group, had transcription-factor JunB (JUNB) as a
target. This transcription factor is part of the family of
the Jun-protein normally identified as a transcriptional
repressor; however, there is evidence that shows its
involvement in the positive transcription regulation of
IL-2, IL-4, IL-6, and TNF-a56–58 and its activation by
external or endogenous stimuli leads to a cellular con-
trol, regulating pathway of differentiation or cell death
(osteoclast and osteoblast genesis and proliferation).59–61
Discussion
The current study is the first to assess preoperative cir-
culating miRNAs as serological preoperative predictors
for postoperative pain relief one year after TKR in pain-
ful knee OA patients. Higher levels of hsa-miR-146a-5p,
hsa-miR-145-5p and hsa-miR-130b-3p were demonstrat-
ed in patients with low-pain relief as compared to
patients with high postoperative pain relief.
Furthermore, preoperative pain intensity was found to
be an independent predictor of postoperative pain relief
with a trend for hsa-miR-146a-5p.
The current analysis highlights that hsa-miR-146a-5p,
hsa-miR-145-5p, and hsa-miR-130b-3p showed higher
preoperatively levels in serum of patients with low post-
operative pain relief one year after TKR. All of these
miRNAs have been assessed in previous study, where
their action to different pathological conditions, for
example, cancer, has been proved through high-
throughput analysis.62–64 As previously stated, these
miRNAs are involved in numerous processes that can
include metabolic, cellular, or pathological processes.
In this study, their involvement in inflammatory process-
es regulation seemed to be of considerable interest since
inflammation is one of the main actors for the sensitiza-
tion of peripheral nerve endings that leads to pain.8
Hsa-miR-146a-5p is codified by a gene located on
chromosome 5 and its mature product differs only by
2–6 nucleotides in the 30 region from the other products
of miRNA-146’s family.65 It has been shown that
Figure 1. Volcano plot of the differential serum miRNAs
expression. Statistical significance versus fold change was showed
on the y- and x-axes, respectively. Volcano plot of data shows the
fold change of the 21 assessed miRNAs in patients with less than
30% pain relief (low-pain relief group) compared with patients with
more than 30% pain relief (high-pain relief group) following total
knee replacement. Three miRNAs exhibited higher significantly
(black dots) expression (P< 0.05) between the two groups.
Table 3. Linear regression models of preoperative pain intensity,
hsa-miR-146a-5p, hsa-miR-130b-3p, and hsa-miR-145-5p aiming to
predict postoperative pain relief in patients with knee osteoar-
thritis following total knee replacement.
Model Variable
Standardized
coefficient P value R2
1 0.29
Preoperative pain intensity 0.522 <0.001
miRNA-146a-5p 0.167 0.096
miRNA-145-5p 0.013 0.889
miRNA-130b-3p 0.91 0.359
2 0.30
Preoperative pain intensity 0.504 <0.001
miRNA-146a-5p 0.183 0.063
Note: Model 1 consists of all the parameters and model 2 is constructed
using backward selection. R2 indicates the combined predictive value.
miRNA: microRNA.
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hsa-miR-146a-5p expression is regulated by nuclear
factor kappa B (NFjB), induced by the action of proin-
flammatory mediators and in response to the activation
of the innate immune response in monocytes and
macrophages.66Hsa-miR-146a-5p has been shown to be
upregulated in synovial tissues of patients with rheuma-
toid arthritis when compared to healthy controls, and its
level of expression is stimulated by inflammatory cyto-
kines such as tumor necrosis factor a (TNF-a) and
Interleukin-1b (IL-1b).67 A previous study has suggested
that suggest that hsa-miR-146a-5p is expressed in OA
cartilage at higher levels than in normal cartilage.68 In
addition, a study found higher levels of miR-146-5p in
peripheral human blood mononuclear cells in early-stage
OA patients when compared with healthy controls, indi-
cating that the dysregulation of miR-146-5p is important
for the initial stage of OA.69 In a mouse model, Lu et al.
showed higher levels of miR-146-5p may partially atten-
uate neuropathic pain conditions in rats by decreasing
the expression of TNF receptor-associated factor 6
(TRAF6).70Hsa-miR-146a-5p also governs feedback of
cytokine expression, and consequently the production of
cartilage–degrading enzymes, such as matrix metallopro-
teinase (MMPs) and a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS).28 The current
study shows that hsa-miR-146a-5p is present at higher
levels circulating in serum of patients with low chronic
postoperative pain relief and shows a trend for this
miRNA as an independent predictor of postoperative
pain relief.
Recent studies have highlighted that high levels
of TNF-a and IL-1b induce the expression of hsa-
miR-145-5p, a pathway involved in the pathogenesis
of OA.34,71 Previously, hsa-miR-145-5p has also been
identified as a regulator of chondrogenic differentiation,
and miRNA microarray data show that hsa-miR-145-5p
is significantly upregulated in human chondrocytes iso-
lated from KOA patients at the last stage (K&L scale III
and IV) of the pathology.71 The expression of hsa-miR-
145-5p is sensitive to the level of TNF-a and is implicat-
ed in modulating the expression of TNF-a-induced
enzymes such as MMPs and ADAMTS, which are
involved in the cartilage disruption and OA progres-
sion.34 Furthermore, the hsa-miR-145-5p expression is
significantly upregulated in OA chondrocytes in
response to IL-1b stimulation, which is important for
cartilage degradation.71–73Has-miR-145-5p have also
been found to be involved in another painful condition
wherein cerebrospinal fluid of patients with fibromyalgia
was strongly downregulated compared with healthy con-
trols, but higher levels of it were found to correlate to
higher levels of pain and fatigue.74 The present results
show preoperative higher expression levels of hsa-miR-
145-5p in the serum of patients with post-operative low-
pain relief, suggesting that hsa-miR-145-5p might
increase and sustain the inflammation in low postoper-
ative pain relief patients causing their painful condition.
However, further studies to confirm this hypothesis are
needed.
Hsa-miR-130b-3p is a well-known marker, studied in
cellular and animal models, involved at different level in
the progression and maintenance of different kinds of
cancer,75,76 but it has also been shown to be involved
in chondrogenesis and osteogenesis,77 associated with
obesity, insulin resistance, and other pathophysiological
processes.45,78 A previous study has shown how
Figure 2. Gene ontology analysis. (a) Bar chart of biological process for genes regulated by hsa-miR-146a-5p. (b) Bar chart of biological
process for genes regulated by hsa-miR-145-5p. (c) Bar chart of biological process for genes regulated by hsa-miR-130b-3p.
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inflammatory signals, such as TNFa and IL-1b, induce
its action in adipose inflamed tissue.44 So far, the
presented results show a higher expression of hsa-
miR-130b-3p in patients with low chronic postoperative
pain relief. Future studies are needed to demonstrate
whether the involvement of this miRNA can be directly
related to the postoperative pain condition in patients
with KOA and then serve as a new biomarker for it.
In this study, before the qRT-PCR, a per sample
quantification of the extracted total RNA was not per-
formed; however, by employing a standardized kit and
several internal control assays (PPC, miRTC, cel-
miR-39-3p), the quality of the qRT-PCR was validated.
Data normalization, a considerable challenge for circu-
lating miRNA data analysis given the lack of robust
house-keeping genes,79,80 was performed using the
common global mean normalization approach.51
Moreover, adjustments for multiple comparisons using
the Benjamini–Hochberg method (false discovery rate,
FDR) was not performed due to the exploratory
nature of this study. Many cell types are capable of
secreting and receiving circulating free and exosomal
miRNAs,18,19,21 which makes it impossible to determine
the tissue origin as well as the recipient cells of the pres-
ently observed dysregulated miRNAs. Future research
on the transporting mechanisms of circulating
miRNAs is needed. With this in mind, in silico target
predictions should be interpreted with caution until
luciferase assays have been conducted on suspected
miRNA-mRNA interactions of interest. In addition,
interactions between miRNA and circulating metabo-
lites released in the blood stream by any pharmaceutical
treatment was not evaluated.
The current study utilized a 30% decrease in pain
after surgery as a cut-off for chronic postoperative
pain. This yielded 16% of patients with chronic postop-
erative pain, which is in line with the overall risk for
chronic postoperative pain following TKR,3 but it is
important to note that different cut-offs have been uti-
lized previously.4,5
Results obtained from this study and the biological
pathways potentially involved in the action of miRNAs
highlighted need to be better investigated and validated
in further studies, and a second independent cohort of
patients. Females were frequent in the current study and
further research is encouraged to address gender differ-
ences in expressions of miRNA in relation to chronic
postoperative pain.
In conclusion, this is the first study to show that post-
operative pain is associated with specific preoperative
serum circulating miRNA signatures. In the subset of
patients who developed chronic pain one year after
TKR, hsa-miR-146a-5p, hsa-miR-145-5p, and hsa-
miR-130b-3p showed higher levels of expression.
Furthermore, a prediction model shows that
preoperative pain intensity is an independent predictive
factor for postoperative pain relief and highlights a trend
for hsa-miR-146a-5p, although further validation analy-
sis is needed in this regard. This exploratory study gives
the first insight into preoperative circulating miRNAs
dysregulation and how they can serve as potential bio-
markers for postoperative pain condition.
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12. Kress M, Hüttenhofer A, Landry M, Kuner R, Favereaux A,
Greenberg D, Bednarik J, Heppenstall P, Kronenberg F,
Malcangio M, Rittner H, €Uçeyler N, Trajanoski Z,
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